These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
125 related articles for article (PubMed ID: 15072460)
21. Inter- and intratumoral disposition of platinum in solid tumors after administration of cisplatin. Zamboni WC; Gervais AC; Egorin MJ; Schellens JH; Hamburger DR; Delauter BJ; Grim A; Zuhowski EG; Joseph E; Pluim D; Potter DM; Eiseman JL Clin Cancer Res; 2002 Sep; 8(9):2992-9. PubMed ID: 12231546 [TBL] [Abstract][Full Text] [Related]
22. Tissue distribution of methotrexate following administration as a solution and as a magnetic microsphere conjugate in rats bearing brain tumors. Devineni D; Klein-Szanto A; Gallo JM J Neurooncol; 1995; 24(2):143-52. PubMed ID: 7562001 [TBL] [Abstract][Full Text] [Related]
23. Transnasal delivery of methotrexate to brain tumors in rats: a new strategy for brain tumor chemotherapy. Shingaki T; Inoue D; Furubayashi T; Sakane T; Katsumi H; Yamamoto A; Yamashita S Mol Pharm; 2010 Oct; 7(5):1561-8. PubMed ID: 20695463 [TBL] [Abstract][Full Text] [Related]
24. The prognostic value of serum methotrexate area under curve in elderly primary CNS lymphoma patients. Kasenda B; Rehberg M; Thürmann P; Franzem M; Veelken H; Fritsch K; Schorb E; Finke J; Lebiedz D; Illerhaus G Ann Hematol; 2012 Aug; 91(8):1257-64. PubMed ID: 22456893 [TBL] [Abstract][Full Text] [Related]
25. Influence of NSAIDs and methotrexate on CD73 expression and glioma cell growth. Lopes DV; de Fraga Dias A; Silva LFL; Scholl JN; Sévigny J; Battastini AMO; Figueiró F Purinergic Signal; 2021 Jun; 17(2):273-284. PubMed ID: 33745072 [TBL] [Abstract][Full Text] [Related]
26. [PEGylated polyamidoamine dendrimer/methotrexate complex: pharmacokinetics and anti-tumor activity in normal and tumor-bearing rodents]. Kong SY; Tang GT; Pei YY; Jiang YY Yao Xue Xue Bao; 2009 Jan; 44(1):85-90. PubMed ID: 19350828 [TBL] [Abstract][Full Text] [Related]
27. CNS penetration of methotrexate and its metabolite 7-hydroxymethotrexate in mice bearing orthotopic Group 3 medulloblastoma tumors and model-based simulations for children. Perkins RS; Davis A; Campagne O; Owens TS; Stewart CF Drug Metab Pharmacokinet; 2023 Feb; 48():100471. PubMed ID: 36669926 [TBL] [Abstract][Full Text] [Related]
29. Tissue distribution and antitumor activity of topotecan delivered by intracerebral clysis in a rat glioma model. Kaiser MG; Parsa AT; Fine RL; Hall JS; Chakrabarti I; Bruce JN Neurosurgery; 2000 Dec; 47(6):1391-8; discussion 1398-9. PubMed ID: 11126910 [TBL] [Abstract][Full Text] [Related]
30. Percutaneous absorption and disposition studies of methotrexate in rabbits and rats. Lu G; Jun HW; Suh H Biopharm Drug Dispos; 1997 Jul; 18(5):409-22. PubMed ID: 9210979 [TBL] [Abstract][Full Text] [Related]
31. Electrical stimulation prolongs the survival days of leukemic mice treated with methotrexate. Uemura N; Nakamura K; Ishii Y; Matsukubo S; Nyu S; Nakano S Jpn J Pharmacol; 1999 Mar; 79(3):269-74. PubMed ID: 10230853 [TBL] [Abstract][Full Text] [Related]
32. Microdialysis-directed Intra-tumor Pharmacokinetic Modeling of Methotrexate in Mice and Humans. Alsulimani HH; Kim J; Sani SN J Pharm Pharm Sci; 2016; 19(2):239-51. PubMed ID: 27518173 [TBL] [Abstract][Full Text] [Related]
33. Selective opening of the blood-tumor barrier by a nitric oxide donor and long-term survival in rats with C6 gliomas. Weyerbrock A; Walbridge S; Pluta RM; Saavedra JE; Keefer LK; Oldfield EH J Neurosurg; 2003 Oct; 99(4):728-37. PubMed ID: 14567609 [TBL] [Abstract][Full Text] [Related]
34. Effect of brain irradiation on blood-CSF barrier permeability of chemotherapeutic agents. Qin D; Ma J; Xiao J; Tang Z Am J Clin Oncol; 1997 Jun; 20(3):263-5. PubMed ID: 9167750 [TBL] [Abstract][Full Text] [Related]
36. Delayed methotrexate excretion in infants and young children with primary central nervous system tumors and postoperative fluid collections. Wright KD; Panetta JC; Onar-Thomas A; Reddick WE; Patay Z; Qaddoumi I; Broniscer A; Robinson G; Boop FA; Klimo P; Ward D; Gajjar A; Stewart CF Cancer Chemother Pharmacol; 2015 Jan; 75(1):27-35. PubMed ID: 25342291 [TBL] [Abstract][Full Text] [Related]
37. Impact of abcc2 [multidrug resistance-associated protein (MRP) 2], abcc3 (MRP3), and abcg2 (breast cancer resistance protein) on the oral pharmacokinetics of methotrexate and its main metabolite 7-hydroxymethotrexate. Vlaming ML; van Esch A; van de Steeg E; Pala Z; Wagenaar E; van Tellingen O; Schinkel AH Drug Metab Dispos; 2011 Aug; 39(8):1338-44. PubMed ID: 21566011 [TBL] [Abstract][Full Text] [Related]
38. Pharmacokinetics of different doses of methotrexate at steady state by in situ microdialysis in a rat model. Ekstrøm PO; Anderson A; Warren DJ; Giercksky KE; Slørdal L Cancer Chemother Pharmacol; 1995; 36(4):283-9. PubMed ID: 7628046 [TBL] [Abstract][Full Text] [Related]
39. Pharmacokinetics of methotrexate after intravenous and intramuscular injection of methotrexate-bearing positively charged liposomes to rats. Kim MM; Lee SH; Lee MG; Hwang SJ; Kim CK Biopharm Drug Dispos; 1995 May; 16(4):279-93. PubMed ID: 7548777 [TBL] [Abstract][Full Text] [Related]
40. Effect of stereotactic implantation of biodegradable 5-fluorouracil-loaded microspheres in healthy and C6 glioma-bearing rats. Menei P; Boisdron-Celle M; Croué A; Guy G; Benoit JP Neurosurgery; 1996 Jul; 39(1):117-23; discussion 123-4. PubMed ID: 8805147 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]